Explore more publications!
Technology Report Cyprus
Got News to Share?

Technology Report Cyprus: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Technology Report Cyprus.

September 2025

Mo Tu We Th Fr Sa Su
1 2 3 4 5 6 7
8 9 10 11 12 13 14
15 16 17 18 19 20 21
22 23 24 25 26 27 28
29 30

October 2025

Mo Tu We Th Fr Sa Su
1 2 3 4 5
6 7 8 9 10 11 12
13 14 15 16 17 18 19
20 21 22 23 24 25 26
27 28 29 30 31

November 2025

Mo Tu We Th Fr Sa Su
1 2
3 4 5 6 7 8 9
10 11 12 13 14 15 16
17 18 19 20 21 22 23
24 25 26 27 28 29 30

Press releases published on October 8, 2025

Nilo Therapeutics se lanza con un financiamiento Serie A de 101 millones de dólares para avanzar una nueva clase de medicamentos dirigidos a los circuitos neuronales en enfermedades inmunológicas y nombra a Kim Seth como director ejecutivo
October 8, 2025

Nilo Therapeutics se lanza con un financiamiento Serie A de 101 millones de dólares para avanzar una nueva clase de medicamentos dirigidos a los circuitos neuronales en enfermedades inmunológicas y nombra a Kim Seth como director ejecutivo

Indeterminate GlobeNewswire
Lancement de Nilo Therapeutics avec un financement de série A de 101 millions de dollars en vue de développer une nouvelle classe de médicaments ciblant les circuits neuronaux dans les maladies immunitaires, et nomination de Kim Seth au poste de…
October 8, 2025

Lancement de Nilo Therapeutics avec un financement de série A de 101 millions de dollars en vue de développer une nouvelle classe de médicaments ciblant les circuits neuronaux dans les maladies immunitaires, et nomination de Kim Seth au poste de…

Indeterminate GlobeNewswire
ナイロ・セラピューティクス (Nilo Therapeutics)、免疫疾患における神経回路を標的とする新しい種類の医薬品開発を推進するため、1億100万米ドル (約154億1,290万円) のシリーズA資金調達を実施し、キム・セス博士 (Kim Seth, Ph.D.) を最高経営責任者 (CEO) に任…
October 8, 2025

ナイロ・セラピューティクス (Nilo Therapeutics)、免疫疾患における神経回路を標的とする新しい種類の医薬品開発を推進するため、1億100万米ドル (約154億1,290万円) のシリーズA資金調達を実施し、キム・セス博士 (Kim Seth, Ph.D.) を最高経営責任者 (CEO) に任…

Indeterminate GlobeNewswire
Nilo Therapeutics dilancarkan dengan pembiayaan Siri A sebanyak $101 juta untuk membangunkan kelas baharu ubat-ubatan yang menyasarkan litar neural dalam penyakit imun, serta melantik Kim Seth sebagai Ketua Pegawai Eksekutif
October 8, 2025

Nilo Therapeutics dilancarkan dengan pembiayaan Siri A sebanyak $101 juta untuk membangunkan kelas baharu ubat-ubatan yang menyasarkan litar neural dalam penyakit imun, serta melantik Kim Seth sebagai Ketua Pegawai Eksekutif

Indeterminate GlobeNewswire
Nilo Therapeutics é lançada com financiamento de US $101 milhões da Série A para promover uma nova classe de medicamentos direcionados a circuitos neurais em doenças imunológicas e nomeia Kim Seth como CEO
October 8, 2025

Nilo Therapeutics é lançada com financiamento de US $101 milhões da Série A para promover uma nova classe de medicamentos direcionados a circuitos neurais em doenças imunológicas e nomeia Kim Seth como CEO

Indeterminate GlobeNewswire
Nilo Therapeutics 啟動 1.01 億美元 A 輪融資，推進針對免疫疾病神經迴路的新型藥物研發，並任命 Kim Seth 為行政總裁
October 8, 2025

Nilo Therapeutics 啟動 1.01 億美元 A 輪融資，推進針對免疫疾病神經迴路的新型藥物研發，並任命 Kim Seth 為行政總裁

Indeterminate GlobeNewswire
Nilo Therapeutics เปิดตัวด้วยการระดมทุนรอบ Series A มูลค่าถึง 101 ล้านเหรียญสหรัฐ เพื่อพัฒนายาประเภทใหม่ที่มุ่งเป้าไปที่วงจรระบบประสาทในโรคภูมิคุ้มกัน รวมถึงแต่งตั้ง Kim Seth เป็นประธานเจ้าหน้าที่บริหา…
October 8, 2025

Nilo Therapeutics เปิดตัวด้วยการระดมทุนรอบ Series A มูลค่าถึง 101 ล้านเหรียญสหรัฐ เพื่อพัฒนายาประเภทใหม่ที่มุ่งเป้าไปที่วงจรระบบประสาทในโรคภูมิคุ้มกัน รวมถึงแต่งตั้ง Kim Seth เป็นประธานเจ้าหน้าที่บริหา…

Indeterminate GlobeNewswire
Nilo Therapeutics 启动 1.01 亿美元 A 轮融资，以推进靶向免疫疾病神经回路的新型药物研发，并任命 Kim Seth 为首席执行官
October 8, 2025

Nilo Therapeutics 启动 1.01 亿美元 A 轮融资，以推进靶向免疫疾病神经回路的新型药物研发，并任命 Kim Seth 为首席执行官

Indeterminate GlobeNewswire
Channel Factory Chosen as Launch Member of the YouTube Activation Partners program
October 8, 2025

Channel Factory Chosen as Launch Member of the YouTube Activation Partners program

Indeterminate GlobeNewswire
Blazer Browser Unveiled: Redefining Speed, Privacy, and Intelligence for the AI Era
October 8, 2025

Blazer Browser Unveiled: Redefining Speed, Privacy, and Intelligence for the AI Era

Indeterminate GlobeNewswire
Apache Gold Casino & Resort Completes Upgrade to QCI’s Latest Release, AGI56
October 8, 2025

Apache Gold Casino & Resort Completes Upgrade to QCI’s Latest Release, AGI56

Indeterminate GlobeNewswire
TransAlta to Host Third Quarter 2025 Results Conference Call
October 8, 2025

TransAlta to Host Third Quarter 2025 Results Conference Call

Indeterminate GlobeNewswire
TruGolf Named Exclusive Golf Technology Supplier to New Golf Everywhere Facility
October 8, 2025

TruGolf Named Exclusive Golf Technology Supplier to New Golf Everywhere Facility

Indeterminate GlobeNewswire
Apogee Therapeutics, Inc. Announces Proposed Underwritten Public Offering
October 8, 2025

Apogee Therapeutics, Inc. Announces Proposed Underwritten Public Offering

Indeterminate GlobeNewswire
374Water Appoints Stephen J. Jones as Interim President and Chief Executive Officer
October 8, 2025

374Water Appoints Stephen J. Jones as Interim President and Chief Executive Officer

Indeterminate GlobeNewswire
Corum Client Frogparking Acquired by Towne Park
October 8, 2025

Corum Client Frogparking Acquired by Towne Park

Indeterminate GlobeNewswire
Sharp Therapeutics to Present Pipeline and Program Updates at World Orphan Drug Congress 2025
October 8, 2025

Sharp Therapeutics to Present Pipeline and Program Updates at World Orphan Drug Congress 2025

Indeterminate GlobeNewswire
LeadSensei Emerges as a Full-Service Growth Platform for Modern Businesses
October 8, 2025

LeadSensei Emerges as a Full-Service Growth Platform for Modern Businesses

Indeterminate GlobeNewswire
Les Prix Profession Santé célèbrent 10 ans d'excellence en soins de santé au Québec
October 8, 2025

Les Prix Profession Santé célèbrent 10 ans d'excellence en soins de santé au Québec

Indeterminate GlobeNewswire
Libtayo® (cemiplimab-rwlc) Approved in the U.S. as First and Only Immunotherapy for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma (CSCC) with a High Risk of Recurrence After Surgery and Radiation
October 8, 2025

Libtayo® (cemiplimab-rwlc) Approved in the U.S. as First and Only Immunotherapy for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma (CSCC) with a High Risk of Recurrence After Surgery and Radiation

Indeterminate GlobeNewswire
Show More

Share us

on your social networks:
Facebook Facebook LinkedIn LinkedIn
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions